Li J et al. have reported that even with a potential 37% decrease in exposure after co-administration of PPIs, there was no difference in efficacy in patients with EGFR-positive NSCLC as evidenced by PFS and OS [45]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.